New results for lung and pancreatic cancer show newer targeted drugs may help some patients live longer. Here is what patients and caregivers should know.
|Videos|November 18, 2019
Reimagining the Possible: A 20-Year Survivor of Pancreatic Cancer
Author(s)Lets Win! Pancreatic Cancer
Advertisement
Marisa Harris is a 20-year plus survivor of stage IV pancreatic cancer. After being told she was medically incurable and untreatable, she took a leave from her job and started researching those who defied the odds and survived. Today Marisa is thriving.
Advertisement
Related to this article
Dr. Robert Kreitman explains how CD22-targeted CAR T could help heavily pretreated patients.
Testicular cancer survivor Brian Sluga shares how faith, journaling and new goals, like training for marathons, helped him live a better life after cancer.
Five phase 3 trials presented at ESMO 2026 showed new options in small cell lung, bladder, prostate, KRAS G12C lung and stomach cancers. Here is what each found and what it means for patients.
An expert discusses infection risks after treatment, what follow-up care looks like and why patients with a rare cancer should ask questions, seek expert opinions and find community.
Median survival, hazard ratio, progression-free survival: a plain-language guide to the terms in cancer trial news, so you can tell what a result means for you and what to ask your care team.
Dr. Robert J. Kreitman explains how an experimental CAR T-cell therapy may help patients with relapsed hairy cell leukemia achieve lasting remissions.
Dr. Jacqueline Barrientos discussed how collaboration, individualized treatment and patient advocacy helped a 72-year-old man achieve leukemia remission and receive a kidney transplant.
Advertisement
Advertisement
Trending on CURE
1
Top 5 Takeaways From ESMO 2026 That Patients Should Know
2
What New KRAS Drug Data From ESMO 2026 Mean for Patients
3
What Liquid Biopsy and ESR1 Mutations Mean in Breast Cancer
4
Psychiatrist Answers Questions About Family and Relationships During Cancer
5